CVS Health said total revenues for the 3 months ended June 30, Q2 2025 were $98,915 million, up 8.4% from $91,234 million in the prior year. GAAP diluted EPS was $0.80, down from $1.41 in the prior year, while Adjusted EPS was $1.81.

1. 01

   CVS Health said total revenues for the 3 months ended June 30, Q2 2025 were $98,915 million, up 8.4% from $91,234 million in the prior year. GAAP diluted EPS was $0.80, down from $1.41 in the prior year, while Adjusted EPS was $1.81.

2. 02

   The company cited litigation charges of $833 million recorded in Q2 2025 related to two court decisions associated with the company's past business practices as the primary factor for the 21.8% decrease in operating income. The company said it plans to appeal both decisions after they become final.

3. 03

   CVS Health revised its full-year 2025 GAAP diluted EPS guidance to $3.84 to $3.94 from $4.23 to $4.43, and raised its Adjusted EPS guidance to $6.30 to $6.40 from $6.00 to $6.20. The company said year-to-date cash flow from operations for the 6 months was $6.5 billion, and it raised its full-year operating cash flow guidance to at least $7.5 billion.

4. 04

   CVS Health said adjusted operating income in Q2 2025 increased to $1,308 million in the Health Care Benefits segment and $1,338 million in the Pharmacy & Consumer Wellness segment, while the Health Services segment declined 17.8% to $1,575 million.

Analysis scope · Filing body and confirmed press-release exhibitWe analyzed the opening part of the filing body and confirmed exhibits, within a length limit. This is not a review of other exhibits, investor presentations or the full earnings call.

AI summarized the filing and translated the summary into English; it may differ from the original. For reference only, not investment advice. AI translated the published Korean report into English. Figures are copied as filed, not recalculated.

Original filing

The filing as submitted to SEC EDGAR. You can check the figures and statements of this summary against it.